In the Field: News - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

In the Field: News

Pharmaceutical Technology
Volume 3, Issue 32

Can They Meet Industry's Interests?



In a recent Pharmaceutical Technology online poll, you—our readers—said Presidential Candidate Mitt Romney would best advance the pharmaceutical industry's interests (26%) as compared to Senator Hillary Clinton (24%), Senator Barack Obama (16%), Senator John Edwards (11%), Senator John McCain (8%), Mike Huckabee (8%) and Rep. Ron Paul (0%). Now that a series of voting primaries across the nation have narrowed the choices for the national Democratic and Republican convention delegates, we'd like to hear more from you. We plan to interview the final candidates later this spring. What would you like us to ask them? Send your questions to
(*At press time, Romney and Edwards had dropped out of the race.)

Facility Roundup



Highlights from the past month's expansion and rationalization announcements.

World Briefs

ASIA & PACIFIC

Tokyo's Eisai acquired MGI Pharma (Bloomington, MN) for approximately $3.9 billion in a cash tender offer followed by a short-form merger of Eisai's acquisition vehicle, Jaguar Acquisition, with MGI PHARMA. As a result, MGI PHARMA became a wholly owned subsidiary of Eisai Corporation of North America. • Contract research organization PPD (Wilmington, NC) expanded its laboratory services into China through an exclusive agreement with Peking Union Lawke Biomedical Development. • Amgen (Thousand Oaks, CA) is partnering with the Osaka, Japan-based research firm Takeda Pharmaceutical Company to develop and commercialize 13 of Amgen's molecules. Takeda is also acquiring all the shares of Amgen's Japanese subsidiary, Amgen KK. • DuPont (Changshu City, China) hopes to establish a broader fluoroproducts-manufacturing base in China with the opening of a fluoropolymer production plant in Changshu City.

EUROPE & MIDDLE EAST

Amira Pharmaceuticals (San Diego, CA) and GlaxoSmithKline (Middlesex, United Kingdom) have agreed to develop, manufacture and commercialize "FLAP" (5-lipoxygenase activating protein) inhibitors for the treatment of respiratory and cardiovascular disease. • Swiss-based Octapharma will relocate its US headquarters to offices in Hoboken, New Jersey. The company's marketing and sales operations moved to Virginia in mid-February. • Dr. Willmar Schwabe Pharmaceuticals (Karlsruhe, Germany) intends to gain access to the United Kingdom market via its recent acquisition of MH Pharma (Marlow, UK). • GE Healthcare (Chalfont St. Giles, UK) has reached agreement to acquire Whatman (Maidstone, UK), a supplier of filtration products and technologies. • FDA issued a warning letter to Novartis Vaccines and Diagnostics (Cambridge, MA) regarding its Marburg, Germany, facility for deviations from current good manufacturing practices, including faulty production and process controls, incomplete failure investigations, and unvalidated cleaning procedures. • PPD (Wilmington, NC) agreed to purchase InnoPharm (Smolensk, Russia), one of the first CROs in Russia and pioneer of implementing good clinical practice in the former Soviet Union. • Natoli Engineering (St. Charles, MO) and Casburt TMS (Stoke-on-Trent, UK), a provider of tablet manufacturing solutions, launched Natoli Europe to cover tablet production, training, and production optimization through the development of a UK-based "Center of Excellence."

LATIN & SOUTH AMERICA

MDS Pharma Services (King of Prussia, PA) established an office in São Paulo, Brazil. The new office is part of the company's nearly two dozen other late-stage clinical trial management offices in 21 countries in Africa, Asia Pacific, Europe, Latin America, and North America.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here